Newsfeed

PHA Canada Announces New Board Chair
The Pulmonary Hypertension Association of Canada (PHA Canada) is pleased to announce that the Board of Directors elected Roberta Massender as their new Board Chair. Massender will serve for a one-year term effective May 26, 2019. She succeeds Dr. Sanjay Mehta who served as chair since 2013. Dr. Mehta will continue to serve on the Board of Directors in the role of Past Chair and Treasurer.
Opsumit Shows Promise for Portopulmonary Hypertension in Phase 4 Trial
Treatment for 12 weeks with Actelion Pharmaceuticals’ Opsumit (macitentan) significantly improved blood vessels’ resistance in patients with portopulmonary hypertension without causing further damage to the liver, data from the PORTICO Phase 4 trial show. The study, “Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial” was published in the journal Lan…
Mouse Study Finds Causal Link Between Iron Levels and Pulmonary Hypertension
A new study in mice demonstrated that a lack of iron in muscle cells lining the circulatory system in the lungs — termed pulmonary arterial smooth muscle cells (PASMCs) — sets off a chain of events that result in pulmonary hypertension (PH). These results suggest a cause-and-effect link between iron deficiency and PH. The study, titled “Intracellular iron deficiency in pulmonary arterial smooth muscle cells induces pulmonary arterial hypert…
Grouped Measures of Clinical Worsening May Help Predict Outcomes in Children with PAH, Study Suggests
A combination of measures of clinical worsening may be meaningful in determining response to therapies in pediatric clinical trials, and a good gauge prognosis in children with pulmonary arterial hypertension (PAH), a registry-based study reports. Disease worsening defined by the occurrence or progression of symptoms, particularly, was found to be a valid predictor of the need for a lung transplant and of death in these patients, the researche…
Iron deficiency linked with cardiovascular disease
A new discovery on how iron deficiency affects the vasculature of the lung could hold the key to improving the treatment of pulmonary arterial hypertension.
The Significance of Databases for PAH
Patients who present with symptoms of pulmonary arterial hypertension could land on any spot of a spectrum which indicates minimal to significant risk of comorbidities, and even mortality. The uncommon, burdensome condition often requires that patients are receiving optimized therapy early and aggressively following diagnosis. That puts pressure on investigators to broaden their access to clinical data. In an interview with MD Magazine®, Rich …
PAH: first global study in epigenetics to treat this disease
On the margins of the World Pulmonary Arterial Hypertension Day, the Quebec Heart and Lung Institute – Laval University (the Institute) is proud to announce the establishment of the first global study in epigenetics on the treatment of pulmonary arterial hypertension (PAH). PAH1 is a complex vascular disease that mainly affects young people between the ages of 20 and 60. These patients’ quality of life remains highly precarious, because of it…
Why Canada needs a comprehensive rare disease strategy
With over 7,000 rare conditions already identified and dozens more being discovered every day, it is estimated that rare diseases impact 1 in 12 Canadians, two-thirds of whom are children. But each disease affects only a handful of individuals, so understanding and medical expertise are limited and uneven across the country. Many of these conditions are associated with lifelong, debilitating symptoms. The burden of each disease is felt not just b…
Balloon Pulmonary Angioplasty Reduces Sleep Apnea in Patients with CTEPH, Study Shows
Balloon pulmonary angioplasty reduces sleep apnea in chronic thromboembolic pulmonary hypertension (CTEPH) patients, according to a study. The observed improvements further correlated with a better mean pulmonary arterial pressure. The results from the study, “Balloon pulmonary angioplasty attenuates sleep apnea in patients with chronic thromboembolic pulmonary hypertension,” was published in the journal Heart & Lung. Sleep apnea, a disorde…
Clinical Development of INOpulse for PH Continues to Move Forward, Bellerophon Reports
Bellerophon released an update on the latest data regarding its INOpulse therapy, and announced its plans to apply for the therapy’s approval as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). INOpulse is a device that uses inhaled nitric oxide (iNO), a potent vasodilator that relaxes blood vessels, to reduce blood pressure in the lungs. It is delivered via a tube in the nose, and uses a…
« Previous123456...47Next »
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png